Tuesday, September 22, 2026 | UTC
About | Contact | API Status
Sign In Subscribe
Live
AAPL $338.98 +0.85%
MSFT $501.61 +1.59%
GOOGL $354.97 +1.55%
AMZN $258.45 +1.87%
TSLA $375.30 +3.03%
META $741.25 +11.34%
NVDA $227.38 +2.30%
JPM $352.04 +0.68%
BTC $38.25 +6.52%
ETH $26.36 +4.69%
AAPL
$338.98
▲ 0.85%
MSFT
$501.61
▲ 1.59%
GOOGL
$354.97
▲ 1.55%
AMZN
$258.45
▲ 1.87%
TSLA
$375.30
▲ 3.03%
META
$741.25
▲ 11.34%
NVDA
$227.38
▲ 2.30%
JPM
$352.04
▲ 0.68%
All Markets Technology Economy Science Health Sports Entertainment Politics
Bloomberg Markets
Lilly's One-Time Cholesterol Treatment
Eli Lilly is developing a groundbreaking one-time gene-editing treatment that could permanently lower bad cholesterol and reduce heart disease risk. Bloomberg's Madison Muller joins Open Interest to break down the science, the risks, and why Lilly is racing to expand beyond obesity drugs into its next major growth era. (Correction: The headline of this video has been edited to clarify the treatment) (Source: Bloomberg)
business  May 26, 2026

Stay ahead of the markets.

Get free access to breaking news, stock data, and market analysis.

Subscribe Free